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ABSTRACT
Age-related macular degeneration (AMD) is the most common cause of blindness, accounting for
8.7% of all blindness globally. Vision loss is caused ultimately by apoptosis of the retinal pigment
epithelium (RPE) and overlying photoreceptors. Treatments are evolving for the wet form of the
disease; however, these do not exist for the dry form. Complement factor H polymorphism in exon
9 (Y402H) has shown a strong association with susceptibility to AMD resulting in complement
activation, recruitment of phagocytes, RPE damage, and visual decline. We have derived and char-
acterized induced pluripotent stem cell (iPSC) lines from two subjects without AMD and low-risk
genotype and two patients with advanced AMD and high-risk genotype and generated RPE cells
that show local secretion of several proteins involved in the complement pathway including factor
H, factor I, and factor H-like protein 1. The iPSC RPE cells derived from high-risk patients mimic
several key features of AMD including increased inflammation and cellular stress, accumulation of
lipid droplets, impaired autophagy, and deposition of “dr€usen”-like deposits. The low- and high-risk
RPE cells respond differently to intermittent exposure to UV light, which leads to an improvement
in cellular and functional phenotype only in the high-risk AMD-RPE cells. Taken together, our data
indicate that the patient specific iPSC model provides a robust platform for understanding the role
of complement activation in AMD, evaluating new therapies based on complement modulation
and drug testing. STEMCELLS 2017;35:2305–2320
SIGNIFICANCE STATEMENT
Age-related macular degeneration (AMD) is one of the most common forms of blindness. Drugs
that treat wet AMD have been a major breakthrough; however, there is currently no treatment
for the dry form. Some of the challenges associated with studying AMD are that the affected
retinal tissue is difficult to obtain, there are no animal models that faithfully mimic the disease,
and human trials are long and costly. This article reports creation of a disease model for AMD
patients with the most common genetic risk factor for the disease. Strong evidence is pre-
sented to show that this model mimics the key features of AMD and can be used to test new ther-
apies and to better understand the pathology of disease and the role of environmental, dietary,
and lifestyle factors.
INTRODUCTION
Age-related macular degeneration (AMD) is
the most common cause of blindness in the
developed world, affecting one in three people
by age 75 years, and is characterized by loss
of central vision, affecting the macular area of
the retina. It accounts for 50% of blind and
partially sighted registration with an estimated
prevalence of 600,000 signiﬁcantly visually
impaired people in the U.K. and over 8 million
worldwide [1–4]. Approximately 70,000 new
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TRANSLATIONAL AND CLINICAL
RESEARCH
diagnoses are made every year in the U.K., and 13% of people
aged over 80 years are affected by late stage AMD. The number
of AMD affected people in the U.K. is expected to rise to 1.3 M
by 2050 with healthcare costs rising to 16.4 billion during 2010–
2020 [5]. Visual loss associated with AMD is caused by apoptosis
of the retinal pigment epithelium (RPE) and overlying photore-
ceptors. AMD occurs in two forms: “dry” AMD where cellular
debris, called dr€usen accumulates between the RPE and Bruch’s
membrane (BrM), appearing as yellow specks on the retina.
“Wet” AMD is usually characterized by aberrant blood vessel
growth and encroachment from the choroid underneath the
retina, although it can also originate from the inner retinal
vasculature. Treatments are evolving for wet AMD including
anti-vascular endothelial growth factor (VEGF) treatments,
photodynamic, and laser therapy [6–8]; however, there are no
effective treatments to prevent progression of the underlying
disease process and advanced dry AMD.
AMD is a multifactorial progressive disease with a com-
plex interaction between environmental, metabolic, hereditary
factors, and chronic innate immune activation [9]. A variety of
alleles and haplotypes associated with early and late AMD
have been identiﬁed from genome wide association studies
(GWAS) [10–13], but the precise roles of these genes and the
mechanisms by which they increase disease risk are ill
deﬁned. One of the most signiﬁcant genetic ﬁndings for AMD
has been the complement factor H (CFH) polymorphisms. CFH
protein functions by limiting the formation of C3 convertase
of the complement system and by promoting the degradation
of C3b to iC3b. Failure to control the activity of C3 convertase
results in overproduction of C3b and C3a causing a shift in
the complement cascade to its terminal lytic pathway. A
signiﬁcantly deleterious consequence of this is the formation
of the anaphylotoxin, C5a, and the membrane attack complex
(MAC) both of which deliver potent inﬂammatory signals. The
T> C substitution in exon 9 (Y402H) of the CFH gene is
strongly associated with susceptibility to AMD and has led to
recognition of the importance of complement activation in
AMD pathogenesis [10]. There is now evidence from large
case–control association studies to conﬁrm association with a
variety of other complement cascade genes including CFHR1–
3, complement factor I (CFI), CFB, C3, and C9 [10, 11]. The
polymorphisms within the 10q26 gene loci containing the
PlEKHA1/HTRA1/ARMS2 genes have also consistently demon-
strated strong associations with AMD in GWAS [10, 12]. In
addition to data gathered from large genetic cohorts,
biochemical and molecular studies have provided substantial
evidence to support an important role for complement activa-
tion in AMD. This is illustrated by the presence of activators
and regulators of the complement system in dr€usen [14] and
the increased expression of MAC proteins in choriocapillaris
and BrM of aged individuals as well as those with the Y402H
polymorphism [15–17].
The Y402H polymorphism can confer more than ﬁvefold
increase risk of developing AMD and is present in approxi-
mately 30% of people of European descent. Although factor H
(FH) protein is synthesized by the choroid, it is not able to
diffuse passively through BrM into the retina; however, its
alternatively spliced, truncated form, named FH-like protein
1 (FHL-1), is able to do so [18]. FHL-1 retains all the necessary
domains for complement regulation and binds to BrM
through interactions with heparan sulphate [18–20]. The
Y402H polymorphism affects the ability of both FH and FHL-1
to bind to heparan sulphate [21]. Furthermore, FH and lipo-
proteins compete for binding to heparan sulphate in BrM
[22]; thus, it has been suggested that impaired binding of FH/
FHL-1 to heparan sulphate in individuals with Y402H polymor-
phism results in fewer binding sites for FH/FHL-1, increased
C3b depositions, lipoprotein accumulation, and failure to
regulate complement activation, leading to recruitment of
mononuclear phagocytes, RPE damage, and visual function
decline.
Recent advances in the ﬁeld of induced pluripotency have
permitted generation of patient speciﬁc induced pluripotent
stem cells (iPSCs), which have the ability to differentiate into
cells of any tissue type including photoreceptors and RPE
[23]. The ability to produce large quantities of functional
patient-speciﬁc retinal cells from iPSCs offers an unparalleled
chance to elucidate disease mechanisms and evaluate new
therapeutic agents. Since the pathogenesis of AMD is largely
unknown, creating a disease model using iPSC technology
could be a valuable tool to address fundamental questions
about disease biology as well as creating a biological tool to
perform drug discovery and toxicity screening. The validity of
this approach has been illustrated by two recent publications
reporting derivation of iPSCs from AMD patients with ARMS2/
HTRA1 high-risk genotypes displaying reduced superoxide
dismutase 2 (SOD2) defense, rendering RPE more susceptible
to oxidative damage [24, 25]. We focused on derivation and
characterization of iPSC from individuals homozygous for the
low- and high-risk CFH (Y402H) polymorphism. When compared
with iPSC-RPE derived from age matched control low-risk indi-
viduals, the high-risk iPSC-RPE cells show a range of cellular,
ultrastructural, and functional deﬁciencies that mimic several
key features of AMD including increased inﬂammation, hall-
marks of cellular stress, accumulation of lipid droplets and
deposition of “dr€usen”-like deposits. Exposure to intermittent
UV light elicited different responses from low- and high-risk RPE
cells and in the latter revealed an improvement in the cellular
and ultrastructural features associated with AMD. Together, our
data suggest that the patient-speciﬁc iPSC disease modeling pro-
vides a robust tool to assess potential therapeutic agents to treat
AMD before long expensive trials.
MATERIALS AND METHODS
Human Donors
Written informed consent was obtained from each donor; all
samples were obtained as part of a NHS research ethics
committee approved biobank for ﬁbroblasts from patients
with retinal disease (ethics number 11/NE/0294) and based at
the Institute of Genetic Medicine, Newcastle University, and
adhered to the tenets set forth in the Declaration of Helsinki.
iPSC Generation
Dermal ﬁbroblasts were isolated from skin biopsies taken from
patients with wet AMD and age-matched donors with no clinical
or genotypic indication of ocular disease (Supporting
Information Fig. S1A, S1B). iPSCs were generated by Sendai viral
transduction of the transcription factors OCT4, SOX2, KLF4, and
c-MYC (ThermoFisher, CytoTune2-iPS Reprogramming Kit,
Waltham, MA, https://www.thermoﬁsher.com/uk/en/home.
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html) following manufacturer’s instructions. iPSCs were main-
tained in deﬁned conditions in mTeSR1 (StemCell Technologies,
Vancouver, Canada, https://www.stemcell.com/) on growth
factor-reduced Matrigel (BD Biosciences, San Jose, CA, http://
www.bdbiosciences.com/us/home).
iPSC Characterization
The pluripotency of iPSC lines was conﬁrmed with immunoﬂuo-
rescence, ﬂow cytometry, and reverse transcriptase polymerase
chain reaction (RT-PCR). Cells were ﬁxed with 4% paraformalde-
hyde for 15 minutes and stained with primary antibodies OCT4
and SSEA4 (Abcam, U.K., http://www.abcam.com/). Primary
antibodies were detected using Alexa Fluor secondary anti-
bodies (Supporting Information Fig. S4B). Nuclei were stained
using 40,6-diamidino-2-phenylindole (DAPI). Images were cap-
tured using a ﬂuorescence microscope (Leica Axiovert, Ger-
many, http://www.leicabiosystems.com/). iPSC were assessed
for their propensity to generate all three germ layers using pri-
mary antibodies against alpha-fetoprotein (AFP), beta III Tubulin
(TUJ1), and smooth muscle actin (SMA), primary antibodies
were detected using Alexa Fluor secondary antibodies (3-Germ
Layer Immunocytochemistry Kit Invitrogen). RT-PCR was used
to detect mRNA transcripts of key pluripotency transcription
factors, NANOG, KLF4, c-MYC, and SOX2 (Supporting Informa-
tion Fig. S4C) and Sendai clearance (Supporting Information
Fig. S5A). RNA was isolated from each iPSC line; RNA was iso-
lated using a column biased method (Promega, http://www.
promega.com/) and 1,000 ng of total RNA was reverse tran-
scribed (GoScript Reverse Transcription System, Promega,
http://www.promega.com/). Standard RT-PCR was performed
and PCR products electrophoresed on a 2% agarose gel.
Directly conjugated antibodies against NANOG (Cell Signal-
ling, http://www.cellsignal.com/) and TRA-1–60 (Millipore,
U.K., http://www.emdmillipore.com/) (Supporting Information
Fig. S4B) were used to detect the percentage population of
pluripotent cells using BD ﬂuorescence-activated cell sorting
(FACS) Canto II (BD Biosciences, San Jose, CA, http://www.
bdbiosciences.com/us/home).
Karyotyping
All cell lines were karyotyped using Illumina CytoSNP analysis
and the BlueFuse Multi 4.3 software (Illumina, San Diego, CA,
https://www.illumina.com/) according to standard protocols of
the manufacturer.
Generation of iPSC-RPE
iPSC were allowed to reach 100% conﬂuency, at which point
the medium was switched from mTeSR1 to RPE differentiation
medium (AdRPMI, ThermoFisher Scientiﬁc, B-27 Supplement)
(ThermoFisher Scientiﬁc, https://www.thermoﬁsher.com/uk/en/
home), 10% knockout serum replacement (ThermoFisher Scien-
tiﬁc), 1% 100X GlutaMAX (ThermoFisher Scientiﬁc, https://
www.thermoﬁsher.com/uk/en/home), and 1% Penicillin–Strep-
tomycin solution (ThermoFisher Scientiﬁc, https://www.thermo-
ﬁsher.com/uk/en/home). Cells were cultured for 16 days with
medium replenished daily for the ﬁrst 14 days. On day 16, the
differentiation medium was supplemented with 2 mM Pur-
morphamine (StemCell Technologies, Vancouver, Canada,
https://www.stemcell.com/) until day 21. Medium was replen-
ished twice a week for the next 3–4 months. RPE patches were
mechanically picked and placed in TryPLE (10X) (Invitrogen,
https://www.thermoﬁsher.com/uk/en/home/brands/invitrogen)
for 30 minutes to dissociate the cells, agitated by gentle
pipetting at 10, 20, and 30 minutes. Cells were sieved using a
100-mm cell strainer and replated at 4.53 105 cells per square
centimeter on 24-well plates or 0.33 cm2 PET hanging cell cul-
ture inserts (Merck Millipore; Billerica, http://www.emdmilli-
pore.com/) coated with PLO/laminin (50 ng/ll) (Sigma-Aldrich,
https://www.sigmaaldrich.com/).
Western Blotting
Supernatant was collected from apical portion of RPE cultures
grown on transwell inserts incubated with Dulbecco’s modiﬁed
Eagle’s medium (DMEM)/F12 for 4 days, soluble proteins were
resolved on BioRad 4%–20% Tris-glycine pre-cast gels nonreduced
(Bio-Rad, http://www.bio-rad.com/) and transferred to nitrocellu-
lose pre-cut blotting membranes (ThermoFisher, http://www.ther-
moﬁsher.com/uk/en/home). Blocking and antibody incubations
were performed using 2% milk solutions. Membranes were incu-
bated with primary antibody at 48C overnight with gentle agitation.
Primary antibodies were detected using applicable horseradish per-
oxidase (HRP)-conjugated secondary antibodies (Supporting Infor-
mation Fig. S4B). Detection of HRP-labeled secondary antibody was
performed with ECL SuperSignal Substrate (Pierce Biotechnology,
http://www.thermoﬁsher.com/uk/en/home/brands/thermo-sci-
entiﬁc/pierce-protein-biology). Bands were identiﬁed by autora-
diography with Carestream Kodak Biomax XAR ﬁlm (Sigma-
Aldrich, http://www.sigmaaldrich.com/) and developed.
DNA Extraction and Sequencing
DNA was extracted using a column biased method (Qiagen,
Germany, https://www.qiagen.com/gb/), sequence tagged PCR
was performed using 100 ng of DNA. Sanger sequencing was
performed (GATC biotech, Germany, http://www.gatc-biotech.
com/en/) and results were interpreted using ﬁnch TV http://
jblseqdat.bioc.cam.ac.uk/gnmweb/download/soft/FinchTV_1.4/doc/
(Geospiza).
Quantitative RT-PCR
RNA was extracted from frozen cell pellets using ReliaPrep RNA
Cell Miniprep System as per the manufactures instructions.
RNA quantiﬁcation was performed with a NanoDrop2000 spec-
trophotometer (ThermoFisher, http://www.thermoﬁsher.com/
uk/en/home). We ensured that the 260/280 ratio and concentra-
tion was between 1.7 and 2.1 and yields of >250 ng/ll. cDNA
synthesis was performed using Promega, http://www.promega.
com/ GoScript Reverse Transcription System as per the manufac-
tures instructions. All experiments were performed using a
QuantStudio 7 Flex Real-Time PCR System (Applied Biosystems,
U.K., http://www.thermoﬁsher.com/uk/en/home/brands/
applied-biosystems), using SYBR green reaction technology
(Promega, U.K., http://www.promega.com/). Cycle parameters
are as follows: 40 cycles of 958C for 15 seconds and 608C for 1
minute, ﬁnalizing with a melt curve stage. The Livak method
(DDCt) was used [26]. Ct results of the target genes were nor-
malized to the Ct of the reference gene GAPDH (DCt); the DCt
obtained then normalized to the DCt of the calibrator, yielding
the (DDCt), ﬁnally the fold difference in expression was deter-
mined (22DDCt ). A list of the primers used can be found in (Sup-
porting Information Fig. S5B).
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RNA Sequencing
RNA was extracted using RNeasy Micro Kit (Qiagen, https://
www.qiagen.com/) according to the manufactures instruc-
tions, from six-cell culture inserts, three of each genotype.
cDNA was generated using SMART-Seq v4 Ultra Low Input
RNA Kit (Clontech, https://www.clontech.com/). Sequencing
was carried out on a NextSeq 500 (Illumina, https://www.illu-
mina.com/). A 75-bp paired-end sequencing was carried out
using a NextSeq 500 High Output v2 Kit (150 cycles) (Illumina,
https://www.illumina.com/). RNA-seq data were processed
and analyzed to identify differentially expressed RNA. The
quality of sequencing reads was ﬁrst checked with FastQC
(Version 0.11.2) [27]. Poly-N tails were trimmed off from
reads with an in house Perl script. Low-quality bases (Q< 30)
and standard Illumina (Illumina, Inc. CA, https://www.illumina.
com/) paired-end sequencing adaptors on 30 ends of reads
were trimmed off using autoadapt (Version 0.2) and only
those that were at least 20 bp in length after trimming were
kept. The high quality reads were then mapped to the human
reference genome hg38 with STAR (Version 2.5.0c) [28]. Reads
mapped to genes were then counted with HTSeq-count (Ver-
sion 0.6.1) [29] according to annotations from GENCODE,
https://www.gencodegenes.org/ (Version 24) [30]. Differentially
expressed genes were identiﬁed with Bionconductor, https://
www.bioconductor.org/ (Version 3.2) package DESeq2 (Version
1.10.1) [31]. Genes differentially expressed in the 99.73 percen-
tile, whereby genes that lie three SDs from the mean (l-3r)
were selected (more than or equal to ﬁvefold change). This
gene list was queried against the protein annotation through
evolutionary relationship classiﬁcation system to highlight dis-
proportionally expressed pathways. RNA-seq data are deposited
into GEO (accession number GSE91087). A list of the overrepre-
sented glycogenesis genes can be found in Table 6.
Pigment Bleaching
Post ﬁxation and before immunocytochemistry, RPE cells were
bleached using a Melanin Bleach Kit (Polysciences, http://
www.polysciences.com/) to remove pigmentation, as melano-
somes can cause excessive autoﬂuorescence. Pretreatment
Solution A was added for 5 minutes at room temperature;
the solution was removed and cells were washed two times
with phosphate-buffered saline (PBS). Pretreatment solution B
was then added for 1–3 minutes until pigmentation was
removed. This solution was removed and cells were washed
again with PBS.
Phagocytosis of Rod Outer Segments
Bovine POS was obtained from InVision BioResources (Seattle,
http://www.invisionbio.com/). Before performing the assay,
POS were FITC labeled using the following procedure. The POS
were centrifuged at 4,500g for 4 minutes. They were then resus-
pended in AdRPMI, 10% fetal bovine serum (FBS) with 0.4 mg/
ml FITC (Sigma, https://www.sigmaaldrich.com/) and incubated
for 1 hour at room temperature protected from light. This was
followed by another centrifugation for 4 minutes at 4,500g. POS
was washed three times with PBS and then resuspended in
2.5% sucrose (Sigma, https://www.sigmaaldrich.com/) in PBS
and stored in 2808C until further use. For phagocytosis experi-
ments, normal RPE cell medium was changed to the POS
medium (AdRPMI, B27, 10% FBS). Once thawed, POS were
resuspended in POS medium. Approximately 1 3 106 FITC-
labeled POS were added per cell culture insert for 4 hours at
378C. In parallel, negative control experiments were performed
where cells were kept for the same duration but at 48C. The
incubations were followed by two cell washes with PBS. Cells
were then dissociated with TrypLE Select Enzyme (10X) (Ther-
moFisher Scientiﬁc, https://www.thermoﬁsher.com/uk/en/
home) and washed. They were then resuspended in 2% FBS
solution in PBS with the addition of DRAQ5 (1:400, BioStatus;
Shepshed, U.K., http://www.biostatus.com/) for 5 minutes.
Extracellular ﬂuorescence was quenched with 0.2% trypan blue
stain (ThermoFisher Scientiﬁc, https://www.thermoﬁsher.com/
uk/en/home) for 10 minutes. Cells were then washed at least
three times with PBS and resuspended in 2% FBS solution in
PBS. Cells were analyzed on a BDTM LSR II ﬂow cytometer (BD
Biosciences; Franklin Lakes, http://www.bdbiosciences.com/us),
collecting at least 10,000 events per sample. The data were ana-
lyzed on BD FACSDiva software (BD Biosciences, http://www.
bdbiosciences.com/us) using following equation
%5
FITC positive
Total number of cells
 
3100
Immunofluorescence
Cells were washed once with PBS, followed by ﬁxation with 4%
paraformaldehyde for 15 minutes at room temperature. Cells
were then washed once with PBS, followed by blocking in 0.25%
Triton-X-100 (Sigma, https://www.sigmaaldrich.com/) and 5%
NGS (Thermo Scientiﬁc, https://www.thermoﬁsher.com/uk/en/
home) in PBS for 1 hour. This solution was removed and replaced
with antibody diluent (0.25% Triton-X-100, 1% bovine serum
albumin in PBS) with applicable antibody dilution; [Anti-ZO1,
rabbit (Invitrogen; dilution 1:200, https://www.thermoﬁsher.
com/uk/en/home/brands/invitrogen), Anti-C5b-9 (Dako 1:200),
Anti-apolipoprotein E (APOE) (Merck Millipore 1:1,000, http://
www.emdmillipore.com/), Anti-LC3 (Cell Signaling 1:250, http://
www.cellsignal.com/), Anti-p62 (1:500)] (Supporting Information
Fig. S4B) at 48C overnight. Cells were washed three times in PBS
followed by incubation with secondary antibodies [CyTM3 Afﬁni-
Pure Goat Anti-Rabbit IgG (Jackson ImmunoResearch, http://
www.jacksonimmuno.com/ (West Grove); dilution 1:1,000),
Anti-mouse IgG–FITC antibody (Sigma; dilution 1:1,000), Donkey
anti-Goat 488 (1:500, Abcam, http://www.abcam.com/), Donkey
anti mouse 647 (Abcam 1:500, http://www.abcam.com/)] for 1
hour at room temperature. Cells were washed as stated
previously and mounted in Vecta sheild (Vector Labs, https://
vectorlabs.com/uk/) with Hoechst 33342 (1:1,000, Thermo Scien-
tiﬁc, https://www.thermoﬁsher.com/uk/en/home), TO-PRO-3
(1:1,000, Thermo Scientiﬁc) or DAPI (Sysmex, 1:1,000, https://
www.sysmex-partec.com). C5b-9 and APOE signals were detected
using a Nikon A1R confocal (resonant, invert) (Nikon, Japan,
https://www.nikoninstruments.com/Applications/Life-Sciences),
45–50 mm optimally sampled. Image processing was performed
using Huygens Essential (Germany, https://svi.nl/Huygens-
Essential) co-localization with the threshold set to 1%.
In Vitro and In Vivo 3 Germ Layer Differentiation
In vitro iPSCs were spontaneously differentiated to allow the
emergence of cell types representative of the three embryonic
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germ layers. iPSCs were allowed to reach 80% conﬂuency after
which the media were switched to DMEM/F12 (ThermoFisher
Scientiﬁc, https://www.thermoﬁsher.com/uk/en/home), 20%
FBS (ThermoFisher Scientiﬁc, https://www.thermoﬁsher.com/
uk/en/home), 1% Penicillin–Streptomycin solution (Thermo-
Fisher Scientiﬁc), and 1% MEM non-essential amino acids solu-
tion (ThermoFisher Scientiﬁc, https://www.thermoﬁsher.com/
uk/en/home). Medium was replaced daily for 3 weeks. The 3-
Germ Layer Immunocytochemistry Kit (ThermoFisher Scientiﬁc,
https://www.thermoﬁsher.com/uk/en/home) was used to
detect cells positive for markers of mesoderm, endoderm, and
ectoderm. Brieﬂy, media were removed from cellular mono-
layers, followed by a 15-minute incubation with ﬁxative solu-
tion. Fixative was removed and permeabilization solution was
added for 15 minutes. This was then removed and replaced
with blocking solution for 1 hour, after which the applicable
antibody was added: SMA (mesoderm), AFP (endoderm), or
Anti-TUJ1 (ectoderm). Cells were washed three times for 3
minutes in wash buffer. Secondary antibody was then added
(Supporting Information Fig. S4B) for 1 hour, after which the
cells were washed as stated previously and 1–2 drops/ml of
NucBlue was added. Plates were stored at 48C before imaging
on a Zeiss Axioplan microscope, https://www.micro-shop.zeiss.
com. All incubations occurred at room temperature unless oth-
erwise stated.
Teratoma Formation in Immunodeficient Mice
All procedures were approved and conformed to institutional
guidelines. Approximately 13 106 iPSCs were injected subcutane-
ously into the right ﬂank of adult non-obese diabetic/severe com-
bined immunodeﬁcient mice. All cells were cotransplanted in a
50-ml Matrigel carrier, (BD Biosciences, http://www.bdbioscien-
ces.com/us/home) to enhance teratoma formation. Mice were
killed after 70–90 days, and teratoma tissues were extracted. Ter-
atoma material for histological analysis was ﬁxed in Bouins ﬁxa-
tive [70% saturated picric acid (Sigma, https://www.sigmaaldrich.
com/); 25% formaldehyde (37%/40%, Sigma) and 5% glacial ace-
tic acid (Sigma, https://www.sigmaaldrich.com/)] overnight. Tis-
sues were processed, then sectioned to 6 lm, and then
counterstained with either H&E or Massons trichrome stain. Sec-
tions were assessed using bright ﬁeld microscopy on an Axio
Imager (Lecia, Germany, http://www.leicabiosystems.com/).
Trans-Epithelial Resistance
Trans-epithelial resistance (TER) was measured with a Millicell
ERS-2 Voltohmmeter (Merck Millipore, http://www.emdmilli-
pore.com/). First, the electrical resistance of a blank cell culture
inserts with media in both apical and basal compartments was
measured, after which inserts with cells were measured. A min-
imum of two repeated measurements were made of each
insert. TER was calculated using the following formula:
TER Xcm2
 
5
average blank
average sample
 
3area:
Transmission Electron Microscopy
Cells were ﬁxed with 2% glutaraldehyde and kept at 48C.
Transmission electron microscopy (TEM) including all the cell
processing was performed at Newcastle University Electron
Microscopy Research Services. Ultrathin sections were stained
with heavy metal salts (uranyl acetate and lead citrate) and
imaged on a Philips CM100 TEM.
Statistical Analysis
Shapiro-Wilk test was used to determine normality, for
normally distributed data sets, one-way analysis of variance
(ANOVA) followed by Tukey’s post hoc test was used to
analyze intergroup differences between samples. Two-way
ANOVA was used to compare between samples and treatment
groups. For non-normally distributed data, Wilcoxon matched-
pairs signed rank test was utilized in matched samples, while
Mann Whitney test were used all other times. GraphPad
Prism 7.0 (San Diego, CA, https://www.graphpad.com/scien-
tiﬁc-software/prism/) was used to perform all statistical analy-
ses. Data are presented as mean6 SD and a conﬁdence
interval of 95% was set, and p .05 was considered statistically
signiﬁcant.
RESULTS
Generation of iPSCs from High-Risk AMD Donors
and Unaffected Controls
To investigate how the Y402H polymorphism in CFH leads to
the pathology associated with AMD, DNA was extracted from
donor cell ﬁbroblasts and sequenced to detect single nucleo-
tide polymorphisms in the CFH, HTRA1, and ARMS2 genes
(Supporting Information Fig. S1A). The two homozygous low-
risk donors were selected on the basis of low-risk for all three
single nucleotide polymorphisms (SNPs) rs11200638 (HTRA1),
rs1061170 (CFH), and rs10490924 (ARMS2) and no clinical
manifestation of AMD. The high-risk donors were speciﬁcally
selected as having advanced AMD with unilateral wet AMD
and reticular pseudo-dr€usen (a known high-risk feature for
both types of advanced AMD) in their fellow eyes (Supporting
Information Fig. S1B, S1C0) and high-risk SNP for CFH and low-
risk HTRA1 and ARMS2. The high-risk CFH in combination
with low-risk HTRA1 polymorphism has been consistently
associated with central dr€usen formation in the older age
group [32].
iPSCs were generated from dermal ﬁbroblasts using nonin-
tegrative Sendai viral vectors expressing Yamanaka reprogram-
ming transgenes. Between 20 and 30 clones were generated
from each donor. At least three clones from each individual
were expanded, adapted to feeder free culture conditions and
thoroughly characterized using well established tests of pluripo-
tency including expression of markers by immunocytochemistry
(SSEA4 and OCT4; Supporting Information Fig. S2A), RT-PCR
(NANOG, KLF4, C-MYC, and SOX2) (Supporting Information Fig.
S2B), ﬂow cytometry (SSEA4 and OCT4; Supporting Information
Fig. S2C), and has the ability to differentiate into all three germ
layers in vitro (SMA, TUJ1, and AFP; Supporting Information Fig.
S2D) and in vivo (Supporting Information Fig. S2E), clearance of
Sendai Transgenes (Supporting Information Fig. S2F), and
genetic identity to parent ﬁbroblasts (Supporting Information
Fig. S2G). One clone from each patient was further selected for
differentiation studies. CytoSNP analysis indicated no chromo-
somal rearrangements, losses, or duplications. Our RT-PCR anal-
ysis also indicated that CFH and FHL-1 are not expressed in
iPSCs (Supporting Information Fig. S3A).
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Establishing iPSC-RPE from High-Risk AMD Patients
and Unaffected Controls
iPSCs were differentiated to RPE using a deﬁned serum and
feeder free protocol described in the Materials and Methods
section. The RPE patches were mechanically isolated and
expanded on laminin coated transwell inserts or tissue culture
plates. Hexagonal cells with pigmentation both visible macro-
and microscopically (Fig. 1A, 1B), which expressed the putative
RPE cell markers ZO-1, CRALBP, and BEST1 (Fig. 1C). Polarity in
the RPE cells is important for their physiological function, we
Figure 1. Derivation of age-related macular degeneration (AMD)-induced pluripotent stem cell (iPSC) retinal pigment epithelium (RPE).
(A): Light microscopy images of iPSC-RPE cells derived from low-risk donors (F018 and F116:402Y) and high-risk AMD patients (F180 and
F181:402H). Scale bar5 50 mm. (B): Flatbed scanned images of a representative well from six-well plates, pigmented patches are clearly
visible. Scale bar5 17.4 mm. (C): CRALBP/ZO-1 and BEST1 immunostaining of representative iPSC-derived RPE cells, Scale bar5 25 mm.
(D): Immunoﬂuorescence representative images of iPSC-RPE and orthogonal images along x- and y-axis (green, Na1 K1-ATPase) (blue,
40,6-diamidino-2-phenylindole) Scale bar5 50 mm, A, apical; B, basal. (E): Pigment epithelium-derived factor enzyme-linked immunosor-
bent assay of apical and basal supernatant, concentration nanogram per milliliter. (F): Trans-epithelial resistance data shown as Xcm2
(resistance). Abbreviations: DAPI, 40,6-diamidino-2-phenylindole; PEDF, pigment epithelium-derived factor.
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checked the presence of Na1 K1-ATPase in both low- and high-
risk iPSC-RPE cells and showed apical localization in both (Fig.
1D). iPSC-RPE cells secreted pigment epithelium-derived factor
also known as serpin F1 in a physiologically similar fashion to
adult RPE [33] (Fig. 1E) all cultures. RPE cells form a tight barrier
in the retina which can be measured by TER. We observed no
signiﬁcant differences in TER between RPE derived from high- or
low-risk AMD individuals (Fig. 1F). Phagocytosis assays also indi-
cated that iPSC-RPE were able to phagocytose bovine rod outer
segments with no differences observed between low- and high-
risk AMD donors (data not shown).
Expression of CFH, FH-Like Protein 1, FI,
and C3b in iPSC-RPE Cells
Expression of FH/FHL-1 (Fig. 2A), factor I (FI) (Fig. 2B), and C3
proteins (Fig. 2C) were detected in RPE conditioned superna-
tants derived from both high- and low-risk cultures, indicating
that iPSC-RPE cells secrete the main component and regula-
tors of the alternative complement pathway. Importantly, the
excreted proteins FH and FI were shown to be functional,
indicated by the breakdown of C3b to iC3b (Fig. 2D). CFH,
FHL-1, CFI, and C3 expression were also conﬁrmed at the
mRNA level utilizing quantitative RT-PCR (Fig. 3A–3E). CFI,
CFH, and FHL-1 were all upregulated in high-risk iPSC-RPE
cells (Fig. 3A–3C), a trend also observed in iPSC-RPE derived
from HTRA1/ARMS2 risk genotypes [25]. Interestingly, C3 was
downregulated in high-risk iPSC-RPE, while C5 showed no
signiﬁcant difference (Fig. 3C, 3D). Together, these results add
to the evidence for local complement synthesis in the eye as
documented previously in the literature [34, 35].
Gene Expression Profiles of Cytokines in AMD and
Control iPSC-RPE
High-risk iPSC-RPE had reduced gene expression of mitochon-
drial SOD2 (Fig. 3F), which acts to transform superoxide, a
toxic by-product of oxidative phosphorylation, into less harm-
ful hydrogen peroxide and diatomic oxygen. It has also been
reported that ARMS2/HTRA1 polymorphism leads to
compromized SOD2 response [23], while knockout of SOD2 in
mice is used as an early model of AMD [36]. APOE, a
Figure 2. Expression and secretion of complement proteins by induced pluripotent stem cell (iPSC)–retinal pigment epithelium (RPE)
by Western blotting. (A): Western blot of protein excreted into the medium by RPE cells, anti-factor H (FH) antibody (ab) shows a band
visible at 150 kDa and factor H-like protein-1 visible at 37 kDa. (B): Anti-factor I (FI) ab indicates a band at 65 kDa. (C): C3 is visible at
187 kDa, while C3b is also visible in the positive control at 90 kDa. (D): Western blot of a ﬂuid phase tripartite cofactor assay probed
with anti-C3 ab. Supernatant from age-related macular degeneration patient induced pluripotent stem cell (iPSC)-RPE cells cultured for
48 hours in serum free media was incubated with puriﬁed C3b to test the activity of FI and FH previously demonstrated to be secreted
by these cells (A, B) (lane 6). Activity was conﬁrmed by the generation of a 67-kDa a01 chain and a 40-kDa a02 chain. It is also observed
that these cells had secreted C3 into the supernatant (C) (lane 5). The serum free media alone had no effect on C3 (lane 4). C3b/FH
combined had minimal cleavage (lane 1) and C3b alone was not cleaved (lane 2). C3b/FH/FI combined was able to cleave C3b to the
67-kDa a01 chain and a 40-kDa a02 chain in the positive control (lane 3). Abbreviations: FH, factor H; FHL-1, factor H-like protein 1; FI,
factor I; RPE, retinal pigment epithelium.
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transporter of lipoproteins and fat-soluble vitamins, and
tumor necrosis factor (TNF)-a, a cytokine involved in systemic
inﬂammation and implicated in downregulation of orthoden-
ticle homeobox 2 (OTX2) [37], showed increased expression in
high-risk donors (Fig. 3G, 3H); however, interleukin-18 (IL18),
a cytokine that can suppress VEGF expression and has been
associated with AMD [38] showed no signiﬁcant difference
between genotypes (Fig. 3I). No signiﬁcant changes between
genotypes were observed for VEGF expression (Fig. 3J). IL1b
has a broad spectrum of mediation in cellular function and
has been implicated as an effector of the inﬂammatory
response [39]. We noted a signiﬁcant difference between
Figure 3. Gene expression analysis in low- and high-risk age-related macular degeneration induced pluripotent stem cell (iPSC)-retinal
pigment epithelium (RPE). Data are presented as mean6 SEM, n5 3. Abbreviations: APOE, apolipoprotein E; CFH, complement factor H;
CFI, complement factor I; FHL-1, factor H-like protein 1; IL, interleukin; OTX, orthodenticle homeobox 2; RPE, retinal pigment epithelium;
SOD, superoxide dismutase; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.
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genotypes with high-risk donors expressing IL1b at a higher
level than low-risk RPE (Fig. 3K). Elevated levels of IL-6 are
found in the vitreal ﬂuid of AMD patients and have been
used as predictors of AMD progression [40]; however, we did
not detect any difference in IL6 between genotypes sugges-
ting that the release of this cytokine is likely from another
source such as microglia (Fig. 3L). OTX2 controls essential,
homeostatic RPE genes. There was a slight decrease (although
not signiﬁcant) in OTX2 in high-risk donors, perhaps linked to
TNF-a expression as stated previously (Fig. 3M). RPE65 expres-
sion remained constant in both genotypes (Fig. 3N).
To further probe into the differences between high- and
low-risk RPE cells, we performed RNA-seq studies which identi-
ﬁed 41 genes residing in the 0.3 percentile and 99.7 percentile,
equating to a25.532-fold change or greater and 5.66 or greater,
respectively (Supporting Information Fig. S3C). This analysis
revealed the upregulated expression of CGA (Glycoprotein hor-
mones a-chain) in RPE cells derived from high-risk donors (Sup-
porting Information Fig. S3C). Currently, there is no documented
expression of CGA in RPE cells; however, the expression of
receptor (GNRHR, Gonadotropin-releasing hormone receptor)
has been detected in retinal tissues [41]. Recoverin (RCVRN)
expression, which marks photoreceptor precursors, was also
upregulated in high-risk donors (Supporting Information Fig.
S3C). It is of interest to note that expression of RCVRN has been
observed in RPE cells which were induced to transdifferentiate
to photoreceptors via overexpression of Neurogenin 1 or 3 [40].
RPE cells undergoing this transition have been noted to retain
pigmentation while displaying an elongated cell body and
RCVRN expression in aPVMD2-ngn1 mouse [42, 43]. It is cur-
rently unclear whether increased RCVRN expression in high-risk
AMD-RPE is related to cell fate changes or to an impaired
wound healing response and epithelial to mesenchymal transi-
tion which has already been reported in AMD-RPE [44]. One
family of genes was disproportionately represented in the low-
risk donor including members of the Wnt and Cadherin signaling
pathways [Protocadherin gamma-A3 (PCDHGA3), Protocadherin
beta-8 (PCDHB8), Protocadherin gamma-A6 (PCDHGA6), and
Putative protocadherin beta-18 (PCDHB18P)], implying that low-
risk donors may ﬁnd it easier to form cell–cell junctions when
compared with high-risk RPE; thus, corroborating previously
published data showing disrupted cell to cell junctions and
induction of AMD-associated pathological changes in light
exposed RPE cells [45].
When all genes with >1.5-fold expression changes
between the high- and low-risk iPSC RPE were analyzed using
Enrichr, (OMIM disease) [46], macular degeneration, diabetes
mellitus type 2, and protein glycosylation disorder diseases
were found to be overrepresented in the RNA-seq dataset
(p5 .05475, Supporting Information Fig. S Fig. S3 B). Glycosyl-
transferases are responsible for post-translational glycol modi-
ﬁcation of proteins, and this is considered a location speciﬁc
modiﬁcation as the enzymes required are normally compart-
mentalized. Glycosylation status is suggested to be important
for efﬁcient transport/diffusion of FHL-1 though BrM; FHL-1 is
normally nonglycosylated and passes easily [47], while glyco-
sylated CFH does not. Interfering with this status could be
detrimental to location and diffusion characteristics. Addition-
ally, advanced glycosylation end products are a classical indi-
cation of an aged RPE cell layer [48]. Together, these data
suggest that the in vitro iPSC-RPE model we have created
mimics the disease at the molecular level.
C5b-9 Deposition and APOE Colocalization in AMD
iPSC-RPE
Many investigations have described the proteomic and lipid
composition of dr€usen [49]. APOE is ubiquitously associated
with dr€usen formation and shown to comprise 36% of all pro-
teins found extracellularly [49]. The terminal complement
complex (C5b-C6-C7-C8-C9n, [C5b-9]) is comprised of ﬁve pro-
teins, C5b, C6, C7, and C8, with the ﬁfth, C9 forming a trans-
membrane ring structure. We found the presence of
aggregates that either contained ApoE, C5b-9, or both pro-
teins in low- and high-risk iPSC-RPE; however, the size of
deposits containing both ApoE and C5b 9 was larger in the
high-risk RPE (Fig. 4A–4D). Signiﬁcantly, larger lipid globules
were also detected in high-risk donors compared with low-risk
(Fig. 4E, 4F).
Ultrastructural Changes to AMD iPSC-RPE
TEM showed that the length of microvilli was reduced in RPE
derived from the high-risk donors (Fig. 5A). The mitochondrial
number also decreased (Fig. 5C); however, the area covered
by them was slightly larger in high-risk donors (Fig. 5B) sug-
gestive of fewer but larger mitochondria which could be the
result of age related mitochondrial dysfunction or stress [50].
Long range PCR assays indicated the absence of mitochondrial
DNA deletions in the ﬁbroblasts and RPE derived from both
low- and high-risk individuals (data not shown). We also
observed the formation of asymmetric vacuoles (marked with-
red stars) almost exclusively in RPE generated from high-risk
donors (Fig. 5D–5F). These vacuoles, which are indicative of
“adaptive survival” in response to environmental or oxidative
stress, have also been observed in a SOD2 knockdown mouse
model of early AMD [34]. They have the potential to lead to
vacuolation-mediated cell death; however, our ﬂow cytometric
analysis did not indicate signiﬁcant changes in apoptosis
between low- and high-risk AMD iPSC-RPE (data not shown).
Autophagy Is Upregulated in High-Risk AMD
iPSC-RPE Cells
Due to the increased lipid build-up and ultrastructural changes,
we suspected that autophagy may have a role in AMD patho-
genesis. It has also been documented previously that dysregu-
lated autophagy may sensitize RPE cells to oxidative stress [51].
Autophagy is associated with intra/inter cellular waste removal
and is upregulated during nutrient starvation and general stress
response. In donor ﬁbroblasts, no difference in expression of
two key autophagy markers, LC3 puncta and p62 aggregates
was observed between low- and high-risk donors (Fig. 6A–6D);
however, p62 intensity was higher in low-risk donors (Fig. 6E)
and localized to the nuclei. In the corresponding iPSC-RPE, LC3
puncta and p62 aggregates were greatly upregulated in high-
risk RPE (Fig. 6F–6I) along with the intensity of p62, which was
also increased (Fig. 6J), which potentially suggests a block in
autophagy in high-risk RPE-iPSC.
Response of Low- and High-Risk AMD-RPE Cells
to UV Exposure
UV can induce the generation of reactive oxygen species
(ROS) derived from diatomic oxygen (O2), superoxide anion
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(O2-), hydroxyl, and peroxyl radicals, resulting in DNA damage.
The retina is highly susceptible to photochemical damage due
to continuous light and UV exposure. This photochemical
induction is exacerbated by the retinal oxygen tension (70
mmHg), which is higher than many other tissues, thereby
increasing the probability of ROS formation. Although the
relationship between UV light exposure and AMD is unclear,
epidemiological evidence indicates an association between
the severity of light exposure and the occurrence of AMD
[52]. Light in the visible UV spectrum (441 nm) is deleterious
for RPE cells, being the most energetic radiation reaching the
macula and causes photo-oxidation generating reactive photo-
products including N-retinylidene-N-retinylethanolamine (A2E),
DNA oxidation, and cell apoptosis [53, 54]. Dr€usen and outer
segments are composed largely of lipids (polyunsaturated
fatty acids) and are particularly vulnerable to photo-oxidation
leading to a chain reaction mechanism of lipid peroxidation
and peroxide organic free radical production [55].
To investigate whether UV exposure acts to exacerbate
the gene expression, functional or structural defects observed
in RPE cells derived from AMD patients, we exposed iPSC-RPE
cells continuously to 0.0045 mW/cm2 of 390–410 nm light for
1 hour each day for 5 days which resulted in an increase in
the concentration of intracellular ROS and decreased mito-
chondrial membrane potential (data not shown). Pigmentation
levels can affect the absorption of UV light; however, pigmen-
tation levels between low- and high-risk donors did not differ
signiﬁcantly (p5 .5; Supporting Information Fig. S3D). IL6
Figure 4. Dr€usen-like deposits form in high-risk induced pluripotent stem cell (iPSC)-retinal pigment epithelium (RPE). (A): Volume of apolipopro-
tein E (APOE) and C5b-9 coexpressing deposits in low- and high-risk iPSC-RPE, dashed black line represents clinically signiﬁcant dr€usen size.
High-risk donor iPSC-RPE cells accumulate larger deposits than low-risk, n5 3. (B): Low-risk iPSC-RPE example of F116; blue, 40,6-diamidino-2-
phenylindole (DAPI); red, C5b-9; and green, APOE. Scale bar5 50 mm. (C): High-risk iPSC-RPE example of F181; blue, DAPI; red, C5b-9; and green,
APOE. Scale bar5 50 mm. (D): Secondary antibody only control; blue, DAPI, red, C5b-9; and green, APOE. Scale bar5 50 mm. (E): Oil red O staining,
high-risk donor iPSC-RPE contained larger lipid globules than low-risk donors. (F): Examples of low- and high-risk donor oil red O staining. Scale
bar5 200 mm. Abbreviations: APOE, apolipoprotein E; DAPI, 40,6-diamidino-2-phenylindole.
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expression, a cytokine previously associated with AMD [56],
was increased in response to UV in both low- and high-risk
iPSC-RPE cells (Fig. 7A). SOD2, VEGF, IL18, CFH, and FHL-1
expression increased only in the high-risk RPE cells (Fig. 7B–
7E), suggesting inﬂamasome activation. The expression of CFI
was upregulated only in the low-risk iPSC-RPE cells (Fig. 7F).
No change in APOE, TNF-a, IL1b, CFH, C3, C5, RPE65, or OTX2
expression was observed in both high and low-risk iPSC-RPE
upon UV treatment (Fig. 7G–7N). Mitochondrial area
decreased in both low- and high-risk iPSC-RPE when exposed to
390–410 nm UV light (Fig. 7P), while the overall number of mito-
chondria remained similar (Fig. 7Q). While there was no signiﬁ-
cant increase in the number of vacuoles or dr€usen-like deposits in
low-risk iPSC-RPE cells, in the high-risk iPSC-RPE both parameters
Figure 5. High-risk induced pluripotent stem cell (iPSC)-retinal pigment epithelium (RPE) shows ultrastructural changes in transmission
electron microscopy analysis. (A): Microvilli length (calculated per ﬁeld of view: 100 mm2) is decreased in high-risk donor iPSC-RPE, n5 3.
(B): Mitochondrial area (calculated per ﬁeld of view: 100 mm2) was increased in high-risk donor iPSC-RPE, p5 .0417, n5 3. (C): Mitochon-
drial number (calculated per ﬁeld of view: 100 mm2) was decreased in high-risk donor iPSC-RPE, p5 .0008, n5 3. (D): The number of vacu-
ole structures (calculated per ﬁeld of view: 100 mm2) was greatly increased in high-risk donor iPSC-RPE, p5 .0055, n5 3. (E): Examples of
low-risk iPSC-RPE cells: left hand side, F018; right hand side, F116; Scale bar5 2 mm. (F): Examples of high-risk iPSC-RPE cells: left hand
side, F180; right hand side, F181; red asterisk indicates vacuoles. Scale bar5 2 mm. Abbreviation: FOV, ﬁeld of view.
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decreased signiﬁcantly (below levels observed in the low-risk
iPSC-RPE cultures; Fig. 7R, 7S; Supporting Information Fig. S3E),
which we hypothesize is possibly due to increased expression of
SOD2 and other protective complement proteins (FHL-1, CFH) in
response to UV exposure. Photobiomodulation or optogenetics
has shown that speciﬁc wavelengths of light exhibit physiological
effects on biological systems. Near-infrared, for example, enhan-
ces mitochondrial activity via activation of cytochrome oxidase
[a photoacceptor, due to four redox active metal centres, pre-
sumed to convert bosons (photons) to fermions (electrons and
positrons)], increases in electrons leads accelerated electron
transport and increased generation of ATP [57]. Currently, a pho-
toacceptor, such as cytochrome oxidase, for 390–410 nm light
has yet to be identiﬁed. Traditionally, studies have focused on the
“optical window” biased on absorption and scattering of light in
tissues, which is higher for both in the blue end of the spectrum;
Figure 6. Autophagy is blocked in high-risk induced pluripotent stem cell (iPSC)-retinal pigment epithelium (RPE) cells but not in high-
risk dermal ﬁbroblasts. (A): Examples for ﬂuorescence staining of low-risk ﬁbroblasts: blue, 40,6-diamidino-2-phenylindole (DAPI); green,
LC3; and red, p62. Scale bar5 10 mm. (B): Examples for ﬂuorescence staining of high-risk ﬁbroblasts: blue, DAPI; green, LC3; and red,
p62. Scale bar5 10 mm. (C): The number of LC3 vesicles per cell did not differ between genotypes in iPSC-RPE cells. (D): Number of
p62-positive aggregates per cell was not affected by genotype (E):. The intensity of p62 decreases in high-risk age-related macular
degeneration iPSC-RPE cells. (F): Examples for ﬂuorescence staining of low-risk iPSC-RPE: blue, TO-PRO-3; green, LC3; and red, p62. Scale
bar5 10 mm. (G): Examples for ﬂuorescence staining of high-risk iPSC-RPE: blue, TO-PRO-3; green, LC3; and red, p62. Scale bar5 10 mm.
(H): LC3 aggregates were signiﬁcantly increased in high-risk iPSC-RPE (I) p62 aggregates per cell were signiﬁcantly increased in high-risk
(J) p62 intensity also increased. Abbreviations: iPSC, induced pluripotent stem cell; RPE, retinal pigment epithelium.
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however, the optical properties of the cornea decrease this
scattering effect making blue light physiologically relevant to the
retina. Additionally, microvilli length in high-risk donor cells
increased in response to UV (Fig. 7O). Together, our data suggest
that low- and high-risk iPSC-RPE cells respond differently to UV
light exposure and set precedence for using iPSC-RPE disease
modeling as a platform for testing existing and new therapeutic
regimes.
DISCUSSION
To date, there are no effective treatments that target the under-
lying disease process in AMD. Availability of patient speciﬁc
models which can generate large numbers of RPE cells would
provide a signiﬁcant advance for a better understanding of AMD
physiopathology, the contribution of environmental, lifestyle,
and dietary factors and drug testing. The advent of iPSC technol-
ogy has made the in vitro modeling of many inherited diseases
Figure 7. The response of low- and high-risk retinal pigment epithelium (RPE) to intermittent UV exposure. (A–N): Quantitative reverse tran-
scriptase polymerase chain reaction expression data shown as fold change in relation to low-risk control; data are presented as mean6 SEM,
n5 3, *, p < .05. [Correction made here after initial online publication.] (O): Average length of microvilli per ﬁeld of view (100 mm2), UV expo-
sure increased microvilli length in high-risk induced pluripotent stem cell (iPSC)-RPE cells, p< .0001. (P): Average mitochondrial area per ﬁeld
of view (100 mm2), UV exposure decreased mitochondrial area in both low- and high-risk iPSC-RPE (p 5 .0003 and p5 .0002). (Q): Average
mitochondrial number per ﬁeld of view (100 mm2), UV exposure did not inﬂuence the average number of mitochondria (p5 .9789). (R): Aver-
age vacuole number (calculated per ﬁeld of view: 100 mm2), UV exposure decreased the number of vacuoles in high-risk cells, p5 .0038. (S):
Dr€usen area, UV exposure decreased the deposition of C5b-9 and apolipoprotein E in high-risk iPSC-RPE cells, *, p5 .0002. Abbreviations:
APOE, apolipoprotein E; CFI, complement factor I; FHL-1, factor H-like protein 1; FOV, ﬁeld of view; IL, interleukin; OTX, orthodenticle homeo-
box 2; RPE, retinal pigment epithelium; SOD, superoxide dismutase; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.
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possible; however, to date, this method has predominantly
been viewed as useful to physiopathologies that manifest early
during development or in childhood. Three recent studies have
implemented premature aging approaches to model Parkinson’s
disease [58] and AMD [23] using iPSC, paving the way for model-
ing of complex age related disease.
In this article, we investigated whether iPSC could be
used to provide a disease modeling tool which mimics an
AMD phenotype in the laboratory in the absence and pres-
ence of stress stimuli. Our rationale was to focus on patients
phenotyped with a signiﬁcant risk factor for AMD, such as
Y402H polymorphism in the CFH gene. Using the iPSC derived
RPE cells generated from low- and high-risk donors in the
absence of any stress stimuli, we have been able to conﬁrm
several key cellular features of AMD as follows: (a) increased
expression of inﬂammatory markers (for example IL1b); (b)
lower expression of the protective oxidative stress markers
(SOD2); (c) increased number of stress vacuoles (and their
surface area); (d) increased accumulation of lipid droplets;
and (e) increased expression of LC3 vesicles and higher p62
expression/aggregate suggestive of impaired autophagy. Most
importantly, we were able to identify the formation of depos-
its comprising of components including Apolipoprotein E and
C5b-9, in keeping with dr€usen formation. These deposits occu-
pied a signiﬁcantly higher volume in the RPE derived from
high-risk lines. The presence of dr€usen and its larger volume
in RPE derived from the high-risk iPSC lines, together with
conﬁrmation of key molecular features observed in previous
AMD studies, suggest that this iPSC model closely mimics the
disease phenotype observed in AMD patients.
The complement proteins associated with AMD (FH, FI,
FHR1, FHR3, C2, and C3) are plasma proteins predominantly
produced in the liver; however, biosynthesis at extrahepatic
sites is now well recognized [17, 18]. As with the blood–brain
barrier, the blood–retinal barrier limits access to circulating
plasma proteins, and it has been suggested that local comple-
ment synthesis may be required for its effects in such areas.
Indeed, it has been shown that choroid and RPE as well as
cultured unstimulated RPE cells produce transcripts for most
classical and alternative pathway complement genes [17, 18].
Data summarized in this manuscript indicate that iPSC derived
RPE cells express the active complement proteins and are
able to modulate their expression in response to stress stimuli
without having to rely on secretion from the choroid and dif-
fusion through the BrM as suggested previously [18].
In view of this local complement regulation by RPE cells
themselves, we were interested to assess the response of
low- and high-risk RPE responses to stress stimuli. Since a
trend toward an association between severity of light expo-
sure and AMD has been suggested by epidemiological studies,
we exposed the iPSC-derived RPE to repeated doses of UV for
5 consecutive days. Pigmentation level between the two
groups was not signiﬁcantly different. The low-risk RPE cells
responded by increasing the expression of inﬂammatory
marker IL6 and CFI. More signiﬁcant changes were observed
in high-risk RPE cells, which upregulated the expression of
protective oxidative stress defense protein, SOD2, as well as
CFH and its truncated form, FHL-1, in addition to showing an
improved ultrastructural (increased microvilli length, reduced
number of stress vacuoles, and lower mitochondrial area) and
functional (lower volume of dr€usen-like deposits) properties.
These results indicate that the low- and high-risk AMD-RPE
cells respond very differently to UV exposure and moreover
this provides evidence for UV mediated functional and cellular
improvement of AMD-associated cellular changes in high-risk
AMD-RPE cells. These intriguing results which we attribute to
increased SOD2 expression need to be validated in a larger
number of cell lines derived from additional high-risk donors
over longer intervals and with different UV doses. They do,
however, highlight an important role for increased oxidative
stress defense as a potential therapeutic strategy for AMD,
corroborating recent data obtained with the HTRA1/ARMS2-
iPSC model and exposure to nicotinamide [25].
Several clinical trials attempting to inhibit the complement
pathway have been completed or are under way including
FCFD4514S (anti-CFD [complement factor D]), LFG 316 (anti-
C5), ARC1905 (anti-C5), catalyst protease (anti-C3), and eculizi-
mab (anti-C5) [59, 60]. In particular, Lampalizumab
(FCFD4514S) has been shown to reduce the geographic atro-
phy enlargement in phase II trials of dry AMD in patients who
also have a CFI polymorphism, indicating that inhibition of
complement is a promising approach. Nonetheless, human
clinical trials are complex, expensive, and require prolonged
periods to assess the long-term effect of a therapy in large
numbers of patients with speciﬁc phenotypes to provide a
consistent end point. The assessment is further complicated
by differing progression rates in patients and the uncertain
choice of disease endpoints to assess progression [61]. This is
a signiﬁcant problem and can lead to trials having negative
but disputed conclusions (e.g., the COMPLETE study on Eculi-
zimab for dry AMD) [62]. A robust and well characterized in
vitro model such as the one described herein provides an efﬁ-
cient tool to assess potential therapeutic agents to treat AMD
(such as complement pathway modulation), to better under-
stand disease physiopathology and to test/repurpose drugs.
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